Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederbusinesswire.com
Business Wire Health: Clinical Trials News
Get the latest updates from Business Wire Health: Clinical Trials News directly as they happen.
Follow now 106 followers
Latest posts
Last updated about 13 hours ago
Riassunto: Incyte annuncia il parere favorevole del CHMP per Zynyz® (retifanlimab) per il trattamento di prima linea del carcinoma anale squamocellulare (SCAC) in fase avanzata
about 13 hours ago
MORGES, Svizzera--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha annunciato che il Comitato per i...
Incyte gibt positive CHMP-Stellungnahme zu Zynyz® (Retifanlimab) für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC) bekannt
about 13 hours ago
MORGES, Schweiz--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) hat heute bekannt gegeben, dass das Committee...
Incyte annonce un avis favorable du CHMP concernant Zynyz® (retifanlimab) pour le traitement de première ligne du carcinome épidermoïde du canal anal (SCAC)
about 13 hours ago
MORGES, Suisse--(BUSINESS WIRE)--Incyte (Nasdaq : INCY) a annoncé aujourd'hui que le Comité...
Resumen: Incyte anuncia una opinión positiva de Zynyz® (retifanlimab) del CMUH para tratamiento de primera línea del carcinoma de células escamosas del canal anal avanzado
about 14 hours ago
MORGES (Suiza)--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) anunció hoy que el Comité de Medicamentos...
Samenvatting: Incyte kondigt positief CHMP-advies aan voor Zynyz® (retifanlimab) voor de eerstelijnsbehandeling van gevorderd plaveiselcelcarcinoom van de anus (SCAC)
about 14 hours ago
MORGES, Zwitserland--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) heeft vandaag bekendgemaakt dat het Comité voor geneesmiddelen...
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
about 17 hours ago
SAN DIEGO--(BUSINESS WIRE)-- #Ipsen--Origami Therapeutics Announces Global Collaboration with Ipsen to Advance...
CD137 Targeted Therapy Research Report 2026-2030: Market Opportunities, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insights - ResearchAndMarkets.com
about 17 hours ago
DUBLIN--(BUSINESS WIRE)--The "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms...
MYC Targeting Therapies Market Research Report 2026-2030, Profiles of Genetic Leap, Curigin, IDP Pharma, Incurix, Omega, Panavance, Peptomyc, Suzhou Kintor, Wayfinder Biosciences, WebenPharma - ResearchAndMarkets.com
about 17 hours ago
DUBLIN--(BUSINESS WIRE)--The "MYC Targeting Therapies Market Opportunity, Targeting Approaches, Technology Development Platforms...
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
about 19 hours ago
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment...
Coya Therapeutics Announces $11.1 Million Private Placement
about 21 hours ago
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage...
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
1 day ago
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey...
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
1 day ago
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the...